Literature DB >> 15778348

Stat3 activity in melanoma cells affects migration of immune effector cells and nitric oxide-mediated antitumor effects.

Lyudmila Burdelya1, Maciej Kujawski, Guilian Niu, Bin Zhong, Tianhong Wang, Shumin Zhang, Marcin Kortylewski, Kenneth Shain, Heidi Kay, Julie Djeu, William Dalton, Drew Pardoll, Sheng Wei, Hua Yu.   

Abstract

Infiltration of immune effector cells in tumors is critical for antitumor immune responses. However, what regulates immune cell infiltration of tumors remains to be identified. Stat3 is constitutively activated with high frequency in diverse cancers, promoting tumor cell growth and survival. Blocking Stat3 signaling in tumors in vivo results in tumor growth inhibition that involves killing of nontransfected tumor cells and infiltration of immune effector cells, suggesting that Stat3 activity in tumor cells might affect immune cell recruitment. However, dying tumor cells can also attract immune cells. In this study, we show in isogenic murine melanomas that natural Stat3 activity is associated with tumor growth and reduction of T cell infiltration. Blocking Stat3 signaling in the melanoma cells containing high Stat3 activity results in expression of multiple chemoattractants, leading to increased migration of lymphocytes, NK cells, neutrophils, and macrophages. In addition, blocking Stat3 triggers tumor cells to produce soluble factors capable of activating macrophage production of NO in vitro and in vivo. TNF-alpha and IFN-beta, which are secreted by Stat3-inhibited tumor cells, are able to activate macrophage NO production, whereas neutralizing TNF-alpha in the tumor supernatant from Stat3-blocked tumor cells abrogates nitrite production. Moreover, interrupting Stat3 signaling in tumor cells leads to macrophage-mediated, nitrite-dependent cytostatic activity against nontransduced tumor cells. These results suggest that tumor Stat3 activity affects recruitment of diverse immune effectors and it can be manipulated to activate the effector phase of innate immune responses.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15778348      PMCID: PMC2632804          DOI: 10.4049/jimmunol.174.7.3925

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  40 in total

Review 1.  The intriguing role of polymorphonuclear neutrophils in antitumor reactions.

Authors:  E Di Carlo; G Forni; P Lollini; M P Colombo; A Modesti; P Musiani
Journal:  Blood       Date:  2001-01-15       Impact factor: 22.113

2.  Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells.

Authors:  J G Turner; A L Rakhmilevich; L Burdelya; Z Neal; M Imboden; P M Sondel; H Yu
Journal:  J Immunol       Date:  2001-01-01       Impact factor: 5.422

Review 3.  Nitric oxide-induced apoptosis in tumor cells.

Authors:  V Umansky; V Schirrmacher
Journal:  Adv Cancer Res       Date:  2001       Impact factor: 6.242

Review 4.  Chemokines in the systemic organization of immunity.

Authors:  Daniel J Campbell; Chang H Kim; Eugene C Butcher
Journal:  Immunol Rev       Date:  2003-10       Impact factor: 12.988

Review 5.  Contribution of nitric oxide-mediated apoptosis to cancer metastasis inefficiency.

Authors:  Keping Xie; Suyun Huang
Journal:  Free Radic Biol Med       Date:  2003-04-15       Impact factor: 7.376

Review 6.  STATs in oncogenesis.

Authors:  T Bowman; R Garcia; J Turkson; R Jove
Journal:  Oncogene       Date:  2000-05-15       Impact factor: 9.867

7.  Stat3-mediated Myc expression is required for Src transformation and PDGF-induced mitogenesis.

Authors:  T Bowman; M A Broome; D Sinibaldi; W Wharton; W J Pledger; J M Sedivy; R Irby; T Yeatman; S A Courtneidge; R Jove
Journal:  Proc Natl Acad Sci U S A       Date:  2001-06-12       Impact factor: 11.205

8.  Phosphotyrosyl peptides block Stat3-mediated DNA binding activity, gene regulation, and cell transformation.

Authors:  J Turkson; D Ryan; J S Kim; Y Zhang; Z Chen; E Haura; A Laudano; S Sebti; A D Hamilton; R Jove
Journal:  J Biol Chem       Date:  2001-09-28       Impact factor: 5.157

9.  Induction of p21WAF1/CIP1 and cyclin D1 expression by the Src oncoprotein in mouse fibroblasts: role of activated STAT3 signaling.

Authors:  D Sinibaldi; W Wharton; J Turkson; T Bowman; W J Pledger; R Jove
Journal:  Oncogene       Date:  2000-11-16       Impact factor: 9.867

10.  Inhibition of STAT3 signaling leads to apoptosis of leukemic large granular lymphocytes and decreased Mcl-1 expression.

Authors:  P K Epling-Burnette; J H Liu; R Catlett-Falcone; J Turkson; M Oshiro; R Kothapalli; Y Li; J M Wang; H F Yang-Yen; J Karras; R Jove; T P Loughran
Journal:  J Clin Invest       Date:  2001-02       Impact factor: 14.808

View more
  44 in total

Review 1.  Molecular profiling to identify relevant immune resistance mechanisms in the tumor microenvironment.

Authors:  Thomas F Gajewski; Mercedes Fuertes; Robbert Spaapen; Yan Zheng; Justin Kline
Journal:  Curr Opin Immunol       Date:  2010-12-23       Impact factor: 7.486

2.  Tris (dibenzylideneacetone) dipalladium, a N-myristoyltransferase-1 inhibitor, is effective against melanoma growth in vitro and in vivo.

Authors:  Sulochana S Bhandarkar; Jacqueline Bromberg; Carol Carrillo; Ponniah Selvakumar; Rajendra K Sharma; Betsy N Perry; Baskaran Govindarajan; Levi Fried; Allie Sohn; Kalpana Reddy; Jack L Arbiser
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

3.  Tumor and Host Factors Controlling Antitumor Immunity and Efficacy of Cancer Immunotherapy.

Authors:  Stefani Spranger; Ayelet Sivan; Leticia Corrales; Thomas F Gajewski
Journal:  Adv Immunol       Date:  2016-01-22       Impact factor: 3.543

Review 4.  Cytokine-induced tumor suppressors: a GRIM story.

Authors:  Dhan V Kalvakolanu; Shreeram C Nallar; Sudhakar Kalakonda
Journal:  Cytokine       Date:  2010-04-10       Impact factor: 3.861

Review 5.  Cancer immunotherapy.

Authors:  Thomas F Gajewski
Journal:  Mol Oncol       Date:  2012-01-08       Impact factor: 6.603

6.  The role of STAT3 activation in modulating the immune microenvironment of GBM.

Authors:  Alfred P See; James E Han; Jillian Phallen; Zev Binder; Gary Gallia; Fan Pan; Dilini Jinasena; Christopher Jackson; Zineb Belcaid; Sung Jin Jeong; Chelsea Gottschalk; Jing Zeng; Jacob Ruzevick; Sarah Nicholas; Young Kim; Emilia Albesiano; Drew M Pardoll; Michael Lim
Journal:  J Neurooncol       Date:  2012-10-25       Impact factor: 4.130

Review 7.  Innate and adaptive immune cells in the tumor microenvironment.

Authors:  Thomas F Gajewski; Hans Schreiber; Yang-Xin Fu
Journal:  Nat Immunol       Date:  2013-10       Impact factor: 25.606

8.  Chemokine expression in melanoma metastases associated with CD8+ T-cell recruitment.

Authors:  Helena Harlin; Yuru Meng; Amy C Peterson; Yuanyuan Zha; Maria Tretiakova; Craig Slingluff; Mark McKee; Thomas F Gajewski
Journal:  Cancer Res       Date:  2009-03-17       Impact factor: 12.701

Review 9.  The Next Hurdle in Cancer Immunotherapy: Overcoming the Non-T-Cell-Inflamed Tumor Microenvironment.

Authors:  Thomas F Gajewski
Journal:  Semin Oncol       Date:  2015-06-03       Impact factor: 4.929

Review 10.  STAT3 signaling in immunity.

Authors:  Emily J Hillmer; Huiyuan Zhang; Haiyan S Li; Stephanie S Watowich
Journal:  Cytokine Growth Factor Rev       Date:  2016-05-09       Impact factor: 7.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.